India’s IPO market continues to witness strong momentum in 2026, with healthcare and diagnostics companies attracting growing investor interest. Increasing healthcare awareness, rising diagnostic testing volumes, and expansion in pathology and in-vitro diagnostics are creating significant growth opportunities for companies operating in the medical diagnostics sector.
Against this backdrop, Q-Line Biotec Limited is set to open its IPO on May 21, 2026. Here is a detailed insight into the company, its IPO, and the industry outlook.
About Q-Line Biotec Ltd.
Incorporated in 2010, Q-Line Biotec Limited is engaged in the development, manufacturing, and marketing of a diverse range of diagnostic reagents, consumables, point-of-care devices, and diagnostic equipment.
The company supplies diagnostic equipment and in-vitro diagnostic products directly and through distributors to:
- Diagnostic service providers
- Hospitals
- Medical colleges
Business Segments
- Clinical Chemistry Reagents
- Haematology Reagents
- Immunodiagnostics
- Molecular Diagnostics
- Point-of-Care Devices and Rapid Tests
- Pathology Equipment and IVD Devices
As of December 31, 2025:
- The company had an annual manufacturing capacity of approximately 1.4 million diagnostic kits
- It also had capacity to manufacture 1,200 Selectra Machines annually
The company’s manufacturing and operations teams consist of:
- 126 permanent employees
- 223 third-party workers
Competitive Strengths
- Strong manufacturing and R&D capabilities
- Diversified diagnostic product portfolio
- Pan-India distribution network
- Long-standing customer relationships
- Experienced promoter and management team
Q-Line Biotec IPO Details
Q-Line Biotec IPO is a book-building issue aggregating to ₹214.48 crore and consists entirely of a fresh issue.
The company plans to utilise the proceeds towards working capital requirements, repayment of borrowings, and general corporate purposes.
Important IPO Timeline
| Event | Date |
|---|---|
| IPO Open Date | May 21, 2026 |
| IPO Close Date | May 25, 2026 |
| Allotment Date (Tentative) | May 26, 2026 |
| Initiation of Refunds | May 27, 2026 |
| Credit of Shares to Demat | May 27, 2026 |
| Listing Date (Tentative) | May 29, 2026 |
Key IPO Details
| Particulars | Details |
|---|---|
| Face Value | ₹10 per share |
| Price Band | ₹326 to ₹343 per share |
| Lot Size | 400 Shares |
| Issue Type | Bookbuilding IPO |
| Total Issue Size | 62,53,200 shares (₹214 Cr) |
| Fresh Issue | 59,40,000 shares (₹204 Cr) |
| Listing At | NSE SME |
| Shareholding Pre-issue | 1,70,74,999 shares |
| Shareholding Post-issue | 2,33,28,199 shares |
Issue Reservation
| Category | Shares Offered |
|---|---|
| QIB | 49.99% |
| NII (HNI) | 15.01% |
| Retail (RII) | 35.00% |
| Market Maker | 5.01% |
Lot Size of Q-Line Biotec IPO
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 800 | ₹2,74,400 |
| Retail (Max) | 2 | 800 | ₹2,74,400 |
| S-HNI (Min) | 3 | 1,200 | ₹4,11,600 |
| S-HNI (Max) | 7 | 2,800 | ₹9,60,400 |
| B-HNI (Min) | 8 | 3,200 | ₹10,97,600 |
Q-Line Biotec Ltd. Financials
The company has demonstrated consistent growth in revenue and profitability over recent years, supported by increasing demand for diagnostic products and healthcare testing infrastructure.
Key Company Financials (₹ Crore)
| Period Ended | Dec 31 2025 | Mar 31 2025 | Mar 31 2024 | Mar 31 2023 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Total Income | 236.50 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.10 |
| EBITDA | 64.23 | 71.32 | 37.63 | 32.98 |
| Net Worth | -0.04 | 189.95 | 161.81 | 127.37 |
| Reserves and Surplus | 2.13 | 188.37 | 160.24 | 125.79 |
| Total Borrowing | 243.85 | 164.95 | 96.91 | 73.65 |
Key Performance Indicators (KPI)
| KPI | Dec 31 2025 | Mar 31 2025 |
|---|---|---|
| ROE | 16.88% | 17.66% |
| ROCE | 13.32% | 23.74% |
| Debt to Equity | 1.06 | 0.87 |
| RoNW | 16.88% | 23.74% |
| PAT Margin | 16.65% | 8.97% |
| EBITDA Margin | 27.64% | 22.73% |
IPO Objects of the Issue
| Purpose | Amount (₹ Cr) |
|---|---|
| Funding working capital requirements | 93.50 |
| Repayment of borrowings | 90.00 |
| General corporate purposes | Balance |
Q-Line Biotec Ltd.: Industry Outlook
- India’s diagnostics and in-vitro diagnostics market is witnessing strong growth due to rising healthcare awareness
- Increasing demand for pathology testing and preventive healthcare is supporting industry expansion
- Growth in hospitals, diagnostic labs, and medical colleges is driving demand for diagnostic equipment and reagents
- Indigenous manufacturing of diagnostic products is gaining momentum under healthcare self-reliance initiatives
- Technological advancements in molecular diagnostics and rapid testing are expected to drive future sector growth
Conclusion
Q-Line Biotec Limited operates in the growing diagnostics and healthcare testing segment with a diversified product portfolio and established manufacturing capabilities. The company benefits from strong distribution networks, increasing healthcare demand, and a broad range of diagnostic solutions.
However, investors should carefully evaluate risks such as high borrowing levels, competitive industry dynamics, and valuation concerns due to the absence of listed peers. Based on recent financial performance, the IPO appears fully priced and may be suitable for informed investors with a moderate to high risk appetite and long-term investment horizon.
